tiprankstipranks
Trending News
More News >
Viking Therapeutics (VKTX)
NASDAQ:VKTX
Advertisement

Viking Therapeutics (VKTX) Stock Statistics & Valuation Metrics

Compare
6,386 Followers

Total Valuation

Viking Therapeutics has a market cap or net worth of $3.67B. The enterprise value is $2.16B.
Market Cap$3.67B
Enterprise Value$2.16B

Share Statistics

Viking Therapeutics has 112,444,960 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding112,444,960
Owned by Insiders2.81%
Owned by Institutions0.42%

Financial Efficiency

Viking Therapeutics’s return on equity (ROE) is -0.12 and return on invested capital (ROIC) is -17.12%.
Return on Equity (ROE)-0.12
Return on Assets (ROA)-0.12
Return on Invested Capital (ROIC)-17.12%
Return on Capital Employed (ROCE)-0.17
Revenue Per Employee0.00
Profits Per Employee-2.44M
Employee Count45
Asset Turnover0.00
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Viking Therapeutics is ―. Viking Therapeutics’s PEG ratio is ―.
PE Ratio
PS Ratio0.00
PB Ratio0.00
Price to Fair Value4.98
Price to FCF0.00
Price to Operating Cash Flow-27.22
PEG Ratio

Income Statement

In the last 12 months, Viking Therapeutics had revenue of 0.00 and earned -109.96M in profits. Earnings per share was -1.01.
Revenue0.00
Gross Profit0.00
Operating Income-150.92M
Pretax Income-109.96M
Net Income-109.96M
EBITDA-109.52M
Earnings Per Share (EPS)-1.01

Cash Flow

In the last 12 months, operating cash flow was -5.87M and capital expenditures 0.00, giving a free cash flow of -5.87M billion.
Operating Cash Flow-5.87M
Free Cash Flow-5.87M
Free Cash Flow per Share-0.05

Dividends & Yields

Viking Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.97
52-Week Price Change-33.09%
50-Day Moving Average29.33
200-Day Moving Average36.30
Relative Strength Index (RSI)63.93
Average Volume (3m)4.03M

Important Dates

Viking Therapeutics upcoming earnings date is Oct 22, 2025, After Close (Confirmed).
Last Earnings DateJul 24, 2025
Next Earnings DateOct 22, 2025
Ex-Dividend Date

Financial Position

Viking Therapeutics as a current ratio of 33.09, with Debt / Equity ratio of 0.12%
Current Ratio33.09
Quick Ratio33.09
Debt to Market Cap0.00
Net Debt to EBITDA0.23
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Viking Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Viking Therapeutics EV to EBITDA ratio is -39.83, with an EV/FCF ratio of -49.69.
EV to Sales0.00
EV to EBITDA-39.83
EV to Free Cash Flow-49.69
EV to Operating Cash Flow-49.69

Balance Sheet

Viking Therapeutics has $33.88M in cash and marketable securities with $878.00K in debt, giving a net cash position of -$33.00M billion.
Cash & Marketable Securities$33.88M
Total Debt$878.00K
Net Cash-$33.00M
Net Cash Per Share-$0.29
Tangible Book Value Per Share$8.07

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%

Analyst Forecast

The average price target for Viking Therapeutics is $92.42, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$92.42
Price Target Upside171.58% Upside
Analyst ConsensusStrong Buy
Analyst Count14
Revenue Growth Forecast
EPS Growth Forecast-23.84%

Scores

Smart Score2
AI Score53
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis